| Literature DB >> 20414204 |
Andrew C Chan1, Paul J Carter.
Abstract
The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20414204 DOI： 10.1038/nri2761
Source DB: PubMed Journal: Nat Rev Immunol ISSN： 1474-1733 Impact factor: 53.106